Brexit, COVID-19 and overseas competition are challenging fintech's future, and Britain should act to stay competitive for the sector, a government-backed review said on Friday. Britain's departure from the European Union has cut the sector's access to the world's biggest single market, making the UK less attractive for fintechs wanting to expand cross-border. The review headed by Ron Kalifa, former CEO of payments fintech Worldpay, sets out a "strategy and delivery model" that includes a new billion pound start-up fund and fast-tracking work visas for hiring the best talent globally.
A former client of accused Sydney conwoman Melissa Caddick has spoken out after the 49-year-old was confirmed dead on Friday.
Romania's Orthodox Church will continue immersing infants in water during baptism ceremonies, it said on Thursday, rejecting calls across the country to change the ritual after a six-week-old baby died after being baptised earlier this month. Prosecutors are investigating the case, which has divided Church officials and believers, with tens of thousands of Romanians petitioning the Church to sprinkle water on the babies' heads instead. The majority of Romania's 20 million people are Orthodox Christians and the Church has considerable influence.
Mitsubishi Corp has decided to pull out of the Vinh Tan 3 power plant in Vietnam, two sources familiar with the company's thinking on the matter told Reuters, as it shifts away from carbon intensive businesses in the face of climate change. Mitsubishi's move to exit the estimated $2-billion project shows how willing Japanese companies and financiers are to drop once-strong support for coal, under pressure from shareholders and activists. Japan's big banks regularly topped lending league tables for coal mines and power stations.
To NASDAQ Copenhagen A/S Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 26 February 2021 Company Announcement number 20/2021 Opening of new fixed-rate bonds Realkredit Danmark will open new callable fixed-rate mortgage covered bonds (SDRO) with the following characteristics: CouponSeriesAmortisationClosing dateMaturity1.50%27SAnnuity*31-08-202301-10-20531.00%22SAnnuity31-08-202301-10-2043 *) with option on up to 10 years interest only. The mortgage covered bonds will be issued in DKK from Capital Centre S. The final terms of the bond will be published by announcement of prospectus as soon as they are available. The Executive Board Any additional questions should be addressed to Chief analyst, Hella Gebhardt Rønnebæk, phone +45 45 13 20 68. Attachment Nr. 20_Aabning af ny 1% 2043 22S og 15 % 2053 27S _uk
China's Ant Group is in talks with other shareholders in its new consumer finance unit to bolster the firm's capital as it prepares to fold in its lucrative micro-lending businesses, people familiar with the matter said. Ant plans to bring the bulk of its micro-lending businesses into the unit - equivalent to roughly 1 trillion yuan ($155 billion) in outstanding loans - a move which will allow it to maintain operations nationwide and expand more easily, said two sources. The plans reflect intense regulatory pressure on Ant to rein in some of its operations and subject them to rules and capital requirements similar to those for banks.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Tryg Forsikring A/S - Settlement of Floating Rate Restricted Tier 1 Capital Notes issuance In accordance with the announcement on 24 February 2021, the issue of Tryg Forsikring A/S' Restricted Tier 1 Capital Notes for the amount of SEK 1.000m (the "Transaction") has been settled. Additional information:For further information, visit tryg.com or contact: Investor Relations Officer, Gianandrea Roberti at +45 20 18 82 67 or firstname.lastname@example.org Investor Relations Manager, Peter Brondt at +45 22 75 89 04 or email@example.com This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction pursuant to the Transaction or otherwise in any jurisdiction in which such offer, invitation or solicitation is unlawful. This announcement does not constitute a prospectus, prospectus equivalent document or an exempted document. This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933 (the "US Securities Act"), as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States. About TrygTryg is one of the largest insurance companies in the Nordic region with activities in Denmark, Norway and Sweden. Tryg provides peace of mind and value for more than 4 million customers on a daily basis. Tryg is listed on NASDAQ Copenhagen and 53% of the shares are held by TryghedsGruppen smba. TryghedsGruppen, annually, contributes around DKK 650m to peace of mind purposes via TrygFonden. Notice to U.S. investorsThis announcement does not constitute an offer to sell, or a solicitation of offers to purchase or subscribe for, securities in the United States. The securities referred to herein have not been, and will not be, registered under the US Securities Act, and may not be offered, exercised or sold in the United States absent registration or an applicable exemption from registration requirements. Cautionary note about forward-looking statementsThis announcement (including any information incorporated by reference in this announcement), oral statements made regarding the Transaction, and other information published by Tryg contain statements which are, or may be deemed to be, "forward-looking statements". Forward-looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of the management of Tryg about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Forward looking statements often use words such as "believe", "expect", "estimate", "intend", "anticipate" and words of a similar meaning, and phrases or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved (or, in each case, their negative or other variations). You should not place undue reliance on these forward-looking statements, which reflect the current views of Tryg, are subject to risks and uncertainties about Tryg and are dependent on many factors, some of which are outside of Tryg's control. There are important factors, risks and uncertainties that could cause actual outcomes and results to be materially different. Except as required by law, Tryg undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Attachment Tryg Forsikring AS_settlement of Restricted Tier 1 Notes issuance
African-Australian community leaders are outraged by the video that Trinity College said “wasn’t racially motivated”.
(Bloomberg) -- Global bonds attempted to recover from an aggressive selloff that drove steep losses in Treasuries and U.S. stocks Thursday. Asian shares slumped and U.S. and European futures pointed lower.Benchmark Treasury yields fell back below 1.5% after trading as high as 1.6% Thursday, when a poorly received government auction led to forced selling by holders of mortgage securities. Their Australian equivalents swung amid an unscheduled purchase operation from the country’s central bank, though a mid-session bond rally faded as the day progressed. Japan’s benchmark hovered near its highest level since early 2016. The dollar extended overnight gains.Stocks dropped more than 3% in Japan and Hong Kong, and were weaker across the region. S&P 500 futures slipped after the benchmark closed down 2.5% with tech shares leading losses. The Nasdaq 100 tumbled 3.6%, the most since October, as investors rotated into companies poised to benefit from an end to lockdowns. Still, stocks popular with the day-trader crowd surged once again, with GameStop Corp. doubling at one point before ending 19% higher.Investors are betting on a sharper-than-expected rebound for the global economy, with some growing increasingly worried that accelerating inflation could trigger a pullback in monetary policy support. Federal Reserve officials so far say surging Treasury yields reflect optimism and have stressed that the central bank has no plans to tighten policy prematurely.What Investors Are Watching After the Spike in Treasury Yields“A move of this magnitude is not healthy for markets and equities are rightfully acting negatively to it,” said Matthew Miskin, the co-chief investment strategist at John Hancock Investment Management. “We will be watching to see if the Fed pushes back more meaningfully on the recent rise in yields.”The 10-year U.S. yield adjusted for inflation rose to its highest level since June, a warning sign for riskier assets that have benefited from exceptionally loose financial conditions amid the pandemic.In remarks this week, Federal Reserve Chairman Jerome Powell offered reassurance that policy would continue to be supportive and look beyond a temporary pick-up in inflation, especially from a low base. Nevertheless, money-market traders have now almost fully priced in a first rate hike by the end of next year.Read more: Soaring U.S. Yields Send Risk Assets Warning as Real Rates RiseElsewhere, oil retreated from its the highest in more than a year as traders mulled depleting global inventories. Bitcoin traded below $50,000 again. Gold extended an overnight decline.Some key events to watch this week:Finance ministers and central bankers from the Group of 20 will meet virtually Friday. U.S. Treasury Secretary Janet Yellen will be among the attendees.These are some of the main moves in markets:StocksS&P 500 futures fell 0.4% as of 7:03 a.m. in London. The S&P 500 Index fell 2.5%.Japan’s Topix Index fell 3.2%.S&P/ASX 200 fell 2.4%.South Korea’s Kospi Index fell 2.9%.Hang Seng Index fell 3.2%.Shanghai Composite Index fell 2.1%.CurrenciesThe Bloomberg Dollar Spot Index rose 0.2% after gaining 0.6% Thursday.The euro was 0.2% lower at $1.2150.The British pound fell 0.6% to $1.3934.The Japanese yen was flat at 106.19 per dollar.The offshore yuan rose 0.2% to 6.4786 per dollar.BondsThe yield on 10-year Treasuries slipped four basis points to 1.48%.Australia’s 10-year yield was up 18 basis points at 1.92%.CommoditiesWest Texas Intermediate crude fell 1.5% to $62.60 a barrel.Gold fell 0.5% to $1,761 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Tim Hortons China has completed a new fundraising round from Sequoia Capital China, Tencent Holdings and Eastern Bell Capital, and plans to add more than 200 shops to its network this year, the coffee chain operator said on Friday. The Toronto-based firm, which competes with Starbucks Corp and Coca-Cola's Costa Coffee in China, did not disclose how much cash it had raised, but said the funds would be channeled into building more outlets as well as its digital infrastructure and brand. Tim Hortons has opened more than 150 shops in ten cities since it entered China two years ago, calling them "profitable", but domestic proprietors have complained of tough price competition.
European stock index futures fell more than 1% on Friday, tracking steep losses on Wall Street and in Asian markets as a jump in bond yields and concerns of lofty equity valuations hammered demand for riskier assets. Euro Stoxx 50 futures slumped 1.7% by 0637 GMT, while FTSE futures and DAX futures fell 1.2% and 1.4%, respectively. Asian markets fell to a one-month low, while the dollar rose from a three-year trough as the 10-year Treasury yield hit a one-year high of 1.614%, sparking fears the heavy losses could trigger distressed selling in other assets.
Goodvalley delivered solid results amid challenging 2020 While the year came off to a good start based on high live pig prices, solid volume growth and strong production efficiency, the global outbreak of COVID-19 put an abrupt end to the positive development. Demand for live pigs and pork products dropped across our markets due to reduced consumption, temporary closures of slaughterhouses and very limited export activities. The significant negative impact on demand and prices was further exacerbated by the effects of an outbreak of African Swine Fever in Germany in the second half of the year where we also saw a sharp increase in feed prices. “2020 was a year of unprecedented challenges and unusual market conditions, and we are proud to report strong operational performance and solid financial results based on our dedicated employees’ extraordinary discipline and work efforts during a difficult period,” says CEO Hans Henrik Pedersen. Highlights • Group revenue decreased by 4% to DKK 1,463 million (2019: DKK 1,526 million), and Adjusted EBITDA came to DKK 316 million (2019: DKK 274 million), corresponding to an Adjusted EBITDA margin of 21.6% (2019: 17.9%). • The Polish segment’s revenue declined to DKK 871 million (2019: DKK 925 million), and Adjusted EBITDA came to DKK 114 million (2019: DKK 112 million)corresponding to an increase in Adjusted EBITDA margin of 13.1% (2019: 12.1%), realised despite lower pig prices and a drop in the meat to feed ratio as the low pig prices were not reflected in the feed price, which was stable. • Ukrainian segment revenue came to DKK 461 million (2019: DKK 429 million), and Adjusted EBITDA increased to DKK 161 million (2019: DKK 113 million) corresponding to an Adjusted EBITDA margin of 34.8% (2019: 26.3%) driven by a significant improvement in our arable production due to a strong focus on crop rotation, despite flooding at the beginning of the year, and a significantly improved pig production efficiency which lifted the number of pigs sold per sow. • Revenue in the Russian business declined to DKK 131 million (2019: DKK 172 million) due to the lower volume and a decrease in the average sales price, and Adjusted EBITDA fell to DKK 40 million (2019: DKK 49 million) corresponding to an Adjusted EBITDA margin of 30.5% (2019: 28.5%), primarily caused by the PRRS outbreak, which impacted volumes produced throughout the year and entailed a sharp decline in the number of pigs sold per sow. OutlookIn 2021, Goodvalley expects to generate revenue of DKK 1,450 - 1,600 million and an Adjusted EBITDA of 230-280 million. The outlook is based on expectations of a relatively stable pig price level compared to the average price in 2020 and good production efficiency. The outlook for 2021 is based on an average market price for live pigs of DKK 11.30 per kilo slaughter pig (2020 reported: DKK 11.19 per kilo slaughter pig) and a feed price of DKK 1.66 per kilo (2020 reported: DKK 1.65 per kilo) in the pig division and the prevailing economic situation in Goodvalley’s markets. The outlook is furthermore based on exchange rates for the Group’s key currencies remaining at the closing rates in December 2020 for the full year. Further information Group CFO, Jakob Brasted + 45 76 52 20 00 firstname.lastname@example.org GOODVALLEY AT A GLANCE Goodvalley is an international producer of high-quality pork products operating in Poland, Ukraine and Russia based on Danish production standards. The company is to a large extent self-sufficient and masters the whole production chain from field to fork, from growing crops for feed, breeding and slaughtering pigs including using the manure in biogas facilities to produce electricity and organic fertilizer for the fields. Goodvalley is certified as a carbon neutral company by German TÜV and operates according to the highest standards in terms of animal welfare, transparency in the production and sustainable production methods. Attachments Goodvalley Annual Report 2020 Goodvalley Sustainability Report 2020
Raymart Santiago has become a negligent father since he started dating fellow actor Jodi Sta. Maria, said Claudine Barretto, Santiago’s estranged wife. Santiago and Sta. Maria went public with their relationship in October. A few months later, Barretto said she was displeased with the two because they had broken a promise that they had made, ... This article, Claudine Barretto says Jodi Sta. Maria is ‘not a good influence’ on her ex-husband, originally appeared on Coconuts, Asia's leading alternative media company.
Japanese shares have slumped, logging their biggest daily decline in nearly a year, after a spike in global bond yields spooked investors already uneasy about the market's stretched valuation.The Nikkei average on Friday ended down 3.
(Bloomberg) -- Bitcoin’s rally this year has hit a speed bump, putting it on track for the worst weekly slide in almost a year amid wider losses in risk assets.The largest cryptocurrency slumped as much as 21% this week, the most since March. The wider Bloomberg Galaxy Crypto Index, tracking Bitcoin, Ether and three other cryptocurrencies, is down 23% this week.The price earlier dipped to as low as $45,525, nearing a key Fibonacci level at around $45,000, before recovering some losses to about $46,375 as of 6:21 a.m. in London, according to consolidated pricing compiled by Bloomberg.The rough patch for Bitcoin comes amid wider chaos in global markets, as a surge in bond yields heralds growing expectations that growth and inflation are moving higher and forcing traders to reevaluate their positions across multiple asset classes. The tech-heavy Nasdaq 100 dropped in seven of the past eight sessions as stocks like Tesla Inc. and Peloton Interactive Inc. declined.“Risk-on assets are taking a hit at the moment -- we’re seeing stocks slide and crypto is following,” said Vijay Ayyar, head of Asia Pacific for cryptocurrency exchange Luno in Singapore. “The dollar is strengthening, which is a good indication to expect a slide in Bitcoin and crypto.”Bitcoin’s weakness in the face of market gyrations raises questions about its efficacy as a store of value and hedge against inflation, a key argument among proponents of its stunning fivefold rally over the past year. Detractors have maintained the digital asset’s surge is a speculative bubble and it’s destined for a repeat of the 2017 boom and bust.In a Flash, U.S. Yields Hit 1.6%, Wreaking Havoc Across MarketsWhile Bitcoin is often touted as the new “digital gold,” the yellow metal is winning out at the moment with spot gold holding at $1,764 per ounce, down about 1.1% for the week. The Bloomberg Dollar Spot Index is up 0.4% in the same period, on track for its strongest gain in a month.Heavy selling in the Grayscale Bitcoin Trust, the world’s largest such fund, as well as the expiry of Bitcoin options are also contributing to the volatility, Ayyar said. The trust has slumped 20% this week, with losses at one point racing past its underlying asset, as a once-massive price premium over Bitcoin has evaporated as investors cashed in on those gains, he said.Prominent figures across the financial world have also recently weighed in on Bitcoin.Tesla chief executive Elon Musk said the prices “seem high” on the weekend, seen by some as an initial catalyst for the week’s selloff. Ark Investment Management’s Cathie Wood later said in a Bloomberg interview she was “very positive on Bitcoin” but didn’t disclose whether Ark had made a purchase.Earlier this week, Microsoft Corp. co-founder Bill Gates said in a Bloomberg Television interview he wasn’t a fan of Bitcoin, while Treasury Secretary Janet Yellen said the token was an “extremely inefficient way of conducting transactions.”(Updates pricing, additional analysis.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Solskjaer ‘not sure’ on Edinson Cavani, Donny van de Beek and Scott McTominay fitness
Emre Gürsoy CEO of Agillic Emre Gürsoy, CEO of Agillic:“In 2020, revenue amounted to DKK 50.5 million and total annual recurring revenue (ARR) to DKK 46.5 million. While it has been a year of challenges, our new strategy has already shown results. We completed a financial turnaround, resulting in a positive EBITDA for 2020 as a consequence of a DKK 15.7 million EBITDA improvement. I am pleased to see that our ARR in Q4 increased by DKK 2.4 million due to a combination of winning new clients and uplifting existing clients. With the capital raises in 2020 and January 2021, we have a strong foundation to pursue our strategic growth and internationalisation plans. Our three main financial goals towards 2023 remain: Double-digit percentage growth rate in ARR subscriptions, positive cash flow from operations, and a positive EBITDA.” Announcement no. 8 2021 Copenhagen – 26 February 2021 - Agillic A/S (Nasdaq First North Growth Market Denmark: AGILC) publishes its Q4 results and annual report 2020. In 2020, revenue from subscriptions, gross profit and number of clients were at an all-time high. For the first time since the IPO in 2018, EBITDA in 2020 was positive and amounted to DKK 0.3 million. In Q4 2020, the annual recurring revenue (ARR) increased by DKK 2.4 million compared to Q3 2020. Emre Gürsoy, CEO of Agillic comments:“In 2020, revenue amounted to DKK 50.5 million and total annual recurring revenue (ARR) to DKK 46.5 million. While it has been a year of challenges, our new strategy has already shown results. We completed a financial turnaround, resulting in a positive EBITDA for 2020 as a consequence of a DKK 15.7 million EBITDA improvement. I am pleased to see that our ARR in Q4 increased by DKK 2.4 million due to a combination of winning new clients and uplifting existing clients. With the capital raises in 2020 and January 2021, we have a strong foundation to pursue our strategic growth and internationalisation plans. Our three main financial goals towards 2023 remain: Double-digit percentage growth rate in ARR subscriptions, positive cash flow from operations, and a positive EBITDA.” Performance highlights 2020 2019 2020 2019 DKK million FY FY Change Q4 Q4 ChangeINCOME STATEMENT Revenue subscriptions 43.9 41.2 7% 10.5 10.8 -3% Revenue transactions 5.5 11.2 -51% 1.4 2.4 -42% Other revenue 1.1 1.4 -21% 0.4 0.5 -20%Total revenue 50.5 53.8 -6% 12.4 13.7 -9%Gross profit 44.2 41.7 6% 10.7 10.8 -1%Gross margin 88% 78% - 87% 79% -Employee costs -29.8 -35.8 17% -6.3 -9.0 30%Operational costs -14.1 -21.3 34% -3.9 -6.1 36%EBITDA 0.3 -15.4 0.5 -4.3 Net profit for the year -8.0 -25.1 68% -1.4 -6.5 78%FINANCIAL POSITION Cash1 16.3 -4.0 16.3 -4.0 ARR DEVELOPMENT ARR subscriptions 40.7 45.5 -11% 40.7 45.5 -11% ARR transactions 5.8 9.6 -40% 5.8 9.6 -40%Total ARR2 46.5 55.1 -16% 46.5 55.1 -16%Change in ARR (DKK) -8.6 5.0 - 2.4 3.4 -Change in ARR (%) -16% 10% - 5% 7% - 1. Cash is defined as available funds less bank overdraft withdrawals2. ARR, i.e. the annualised value of subscription agreements and transactions at the end of the actual reporting period Highlights Q4 2020 In Q4, Agillic successfully renewed and uplifted its two largest clients as well as other strategically important clients. Seven new client contracts across several industries were signed, in Denmark and internationally. As of 31 December 2020, Agillic had 82 clients, which is an all-time high.ARR increased by DKK 2.4 million in Q4 compared to Q3 2020 (+5%). The net uplifts and new clients increased the subscription part of ARR from DKK 40.1 in Q3 to 40.7 million in Q4. The transaction part of ARR was higher than Q3 due to the seasonality of Black Week and Christmas. This year, Agillic’s Customer Marketing Platform again delivered a high performance to all clients during Q4.The Company moved to new facilities. Financial Highlights FY 2020 Total revenue amounted to DKK 50.5 million compared to 53.8 million (-6%) in 2019. However, revenue from subscriptions increased by 7% to DKK 43.9 million, which was an all-time high.Gross profit was at an all-time high, with DKK 44.2 million for the year (+6%).EBITDA amounted to DKK 0.3 million, an improvement of DKK 15.7 million compared to year-end 2019. The positive development resulted from an improved gross profit of DKK 2.5 million and reduced operational costs of DKK 13.2 million. It is the first time since the IPO in 2018 that the Company can present a positive EBITDA.Time to recover CAC declined from 18 months to 12 months.As of 31 December 2020, ARR amounted to DKK 46.5 million.As of 31 December 2020, cash at bank amounted to DKK 16.3 million. Comments on ARR development As of 31 December 2020, ARR amounted to DKK 46.5 million, compared to DKK 55.1 million as of 31 December 2019, a decrease of DKK 8.6 million (-16%), which was mainly driven by COVID-19 and its negative impact on the retail and travel & leisure segments.The transactional part of ARR was also lower in Q4 2020 than Q4 2019 due to the impact of COVID-19, especially on the above-mentioned segments.Although Agillic won 20 new clients in 2020, the subscription part of the ARR decreased. Following the business impact of COVID-19, some clients downgraded, and some clients churned. Seeking to offset the negative effect of COVID-19, Agillic focused on adjusting the subscription fees in exchange for an increase in the clients’ subscription period commitment. Financial guidance 2021 & 2022The Company published its financial guidance on 19 January 2021 DKK million20212022Revenue49 - 5357 - 63EBITDA-5 to -1-3 to +3 ARR subscriptions45 - 49 ARR transactions5 - 7 Total ARR*50 - 5665 - 70Growth rate in total ARR 30-40% *) The growth rate in ARR subscriptions is expected to be higher than in ARR transactions. Strategy toward 2023 Since the Initial Public Offering (IPO) in March 2018, Agillic has pursued growth and internationalisation. Apart from the domestic market, markets of particular interest are the DACH region, North America, Norway, Sweden, the UK, and, as of 2021, Central and Eastern Europe. Together with Agillic’s strategic partners across geographies, the Company continues to target digitally mature and data-driven B2C-businesses with a substantial customer base within the following sectors: retail, finance, travel & leisure, NGO & charities and subscription businesses. Please find Agillic’s annual report 2020 here:Agillic annual report 2020 Financial calendar 2021 Annual general meeting: 30 March 2021 Financial results 1st quarter 2021: 4 May 2021 Half-year report 2021: 26 August 2021 Financial results 3rd quarter 2021: 22 October 2021 For further information, please contact:Emre Gürsoy, CEO, Agillic A/S +45 30 78 42 00 email@example.com Bent Faurskov, CFO, Agillic A/S+45 25 16 21 03 firstname.lastname@example.org Certified AdviserJohn Norden, Norden CEFKongevejen 365, 2840 HolteDenmark+ 45 20 72 02 email@example.com Disclaimer The forward-looking statements regarding Agillic’s future financial situation involve factors of uncertainty and risk, which could cause actual developments to deviate from the expectations indicated. Statements regarding the future are subject to risks and uncertainties that may result in considerable deviations from the presented outlook. Furthermore, some of these expectations are based on assumptions regarding future events, which may prove incorrect. Please also refer to the overview of risk factors in the ‘risk management’ section of the annual report. About Agillic A/S Agillic is a Danish software company enabling marketers to maximise the use of data and translate it into relevant and personalised communication, thereby establishing strong relations between people and brands. Our customer marketing platform uses AI to enhance the business value of customer communication. By combining data-driven customer insights with the ability to execute personalised communication, we provide our clients with a head start in the battle of winning markets and customers. Besides the Company’s headquarters in Copenhagen, Denmark, Agillic has sales offices in London (UK) and Stockholm (Sweden), as well as a development unit in Kyiv (Ukraine). For further information, please visit www.agillic.com. Agillic A/S (publ) (Nasdaq First North Growth Market Denmark: AGILC) is obligated to publish the above information in compliance with the EU Market Abuse Regulation. The information was published via agent by Agillic A/S on 26 February 2021. Appendix: Financial development per quarter 2018 2019 2020 DKK million Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4INCOME STATEMENT Revenue subscriptions 5.9 6.3 6.6 8.7 9.3 10.5 10.6 10.8 12.0 10.8 10.5 10.5 Revenue transactions 1.9 2.2 2.0 2.6 3.1 3.4 2.2 2.4 2.2 0.8 1.0 1.4 Other revenue 0.4 1.0 0.5 0.8 0.4 0.3 0.2 0.5 0.5 0.1 0.2 0.4Total revenue 8.2 9.5 9.1 12.2 12.8 14.3 13.0 13.7 14.7 11.8 11.7 12.4Gross profit 5.3 7.2 7.1 9.7 9.7 11.1 10.1 10.8 11.9 11.1 10.5 10.7Gross margin 65% 76% 78% 79% 76% 78% 78% 79% 81% 94% 90% 87%EBITDA -5.4 -4.0 -3.4 -6.3 -3.5 -4.8 -2.8 -4.3 -0.4 0.6 -0.4 0.5Net profit for the year -7.2 -6.1 -5.8 -6.7 -5.9 -8.6 -4.1 -6.5 -2.7 -0.5 -3.4 -1.4 BALANCE SHEET Cash1 35.1 24.1 15.6 12.3 2.7 1.0 -1.0 -4.0 -6.1 15.2 14.8 16.3Total assets 60.4 53.9 50.0 47.4 36.1 40.5 40.9 37.7 38.4 59.3 55.7 63.8Equity 21.4 15.4 9.9 3.5 -2.1 -10.5 -14.3 -20.6 -18.7 -1.4 -4.6 -5.8Borrowings 13.0 11.6 9.0 11.3 10.5 16.3 21.3 24.4 28.5 28.3 28.9 28.9 EMPLOYEES & CLIENTS Employees end of period 33 43 50 56 60 63 67 64 64 61 57 53Clients end of period 55 59 65 73 73 79 77 81 84 83 79 82 ARR & SAAS METRICS ARR subscriptions 27.6 29.5 33.4 39.6 40.7 44.5 43.0 45.5 47.0 43.6 40.1 40.7 ARR transactions 7.4 9.3 8.5 10.5 12.6 13.8 8.7 9.6 8.9 3.3 4.0 5.8Total ARR2 35.1 38.8 41.9 50.1 53.3 58.2 51.7 55.1 55.8 46.9 44.1 46.5Change in ARR (DKK) 1.9 3.7 3.1 8.2 3.2 5.0 -6.5 3.4 0.8 -8.9 -2.8 2.4Average ARR3 0.6 0.7 0.6 0.7 0.7 0.7 0.7 0.7 0.7 0.6 0.6 0.6Yearly CAC4 0.5 0.8 0.5Months to recover CAC5 11 18 12 1. Cash is defined as available funds less bank overdraft withdrawals.2. ARR, i.e., the annualised value of subscription agreements and transactions at the end of the actual reporting period.3. Average ARR, i.e. the average ARR per client.4. Customer Acquisition Costs (CAC), i.e., the sales and marketing cost (inclusive salaries, commissions, direct and share of costs of office divided by the number of new clients. CAC is calculated end of year. Former CAC numbers have been restated. 5. Months to recover CAC YTD, i.e., the period in months it takes to generate sufficient gross profit from a client to cover the acquisition cost. Attachments Emre Gürsoy CEO of Agillic Company Announcement no 8 2021 Agillic Annual Report 2020
Right now Teladoc Health is the dominant name in virtual healthcare. Are there any internet companies that might dislodge Teladoc from its leadership position?
Stockholm, February 26, 2021 – Anoto Group AB (“Anoto” or the “Company”) announces that the Company’s total number of shares and votes has increased by 30,000,000 shares and votes, respectively. The number of shares and votes in Anoto has increased as a result of the directed rights issue resolved by the Company’s board of directors on December 28, 2020, based on an authorization from the Annual General Meeting held on May 18, 2020, and announced through the press release of December 29, 2020, together with the directed rights issue resolved by the board of directors on January 20, 2021, announced through the press release of the same date and approved by the Extraordinary General Meeting held on February 15, 2021. As of February 26, 2021, the total number of shares and votes in Anoto amounts to 215,658,150 shares and votes, respectively. For further information, please contact: Johannes Haglund, Chief of Staff, Anoto Group AB For more information about Anoto, please visit www.anoto.com or email firstname.lastname@example.org Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, SE-116 74 Stockholm This information is information that Anoto Group AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, on February 26, 2021 at 08:00 CET. About Anoto GroupAnoto is a publicly held Swedish technology company known globally for innovation in the area of information-rich patterns and the optical recognition of those patterns. It is a leader in digital writing and drawing solutions, having historically used its proprietary technology to develop smartpens and the related software. These smartpens enrich the daily lives of millions of people around the world. Anoto currently has three main business lines: Livescribe retail, Enterprise Forms and OEM. Anoto also owns Knowledge AI, a leading AI based education solution company, as its majority-controlled subsidiary. Anoto is traded on the Small Cap list of Nasdaq Stockholm under ANOT. Attachment Change in number of shares and votes_February 2021 (En)
PARIS and CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces its non-audited financial results for the year ended December 31, 2020, and provides updates on key operational developments and financing transactions. • Major milestones achieved during 2020 Launch of the phase 2-3 COVA trial assessing Sarconeos (BIO101) as a potential treatment for acute respiratory failure linked to COVID-19 global, multicenter, double-blind, placebo-controlled, group-sequential and adaptive design two-part Phase 2-3 study approved in 5 countries: the US, Brazil, France, Belgium and the UKPatient enrollment for Part 1 completed with 50 patients, and trial moving to Part 2 following approvals from certain Regulatory AuthoritiesInterim Analysis of Part 1 expected in Q1 2021 and results from the full study (Part 1 and Part 2) expected in Q2 2021, subject to any delays in patient recruitment or retention, interruptions in sourcing or supply chain, regulatory authorizations and procedures, COVID-19-related delays, and the impact of the current pandemic Treatment completed for the last patient in the Phase 2 SARA-INT trial for the treatment of sarcopenia. Top-line results expected in Q2 2021Successful completion of four private placements, significantly strengthening company financial resources, with total cash and cash equivalents and other current financial assets amounting to €18.8 million as of December 31, 2020 • Successful IPO on Nasdaq Capital Market closed on February 12, 2021 for total gross proceeds of $20.1 million Stanislas Veillet, President and CEO of Biophytis, said: “2020 marked a turning point for Biophytis. Four successful private placements have allowed us to strengthen our financial situation in order to enter a new and exciting phase in the development of the company. At the same time, we have been making strong progress in clinical operations. We are proud to participate in the world fight against SARS-CoV-2 through the launch of COVA, our phase 2-3 study assessing Sarconeos (BIO101) as a potential treatment for patients with severe respiratory manifestation of COVID-19. The study is now entering Phase 3 in Brazil, the United States, France and Belgium, and full results are expected in Q2 2021. Our last patient completing last visit in the SARA-INT Phase 2 trial in sarcopenia is also an important milestone, and we look forward to top-line results which are also expected in Q2 2021.” The Company’s annual 2020 non-audited consolidated financial statements prepared in accordance with IFRS were reviewed by the Company’s Board of Directors on February 23, 2021. Audit procedures are being completed, the issuance of the audit report is pending, and will be included in the Company’s upcoming 2020 annual financial report and SEC Form 20-F. Annual 2020 Financial Results • Cash and cash equivalents and other current financial assets. Cash and cash equivalents and other current financial assets as of December 31, 2020 were €18.8 million, an increase of €12 million compared to €6.8 million as of December 31, 2019. During 2020, cash used in operating activities was €9.9 million. Cash used in investment activities was €12.7 million, of which €12.5 million are linked to fixed term deposit contracts. These uses were offset by €22.1 million of cash provided by financing activities. • Research and Development Expenses. Net research and development expenses were €9.9 million for 2020, an increase of €0.8 million, or 9%, compared to €9.1 million for 2019. This increase is mainly linked to the launch of the COVA program. In parallel, SARA-INT, our Phase 2 trial in Sarcopenia is progressing. Patients recruitment was completed in March 2020, and the last dosing of our last patient was achieved in December 2020. Net research and development expenses included research tax credits (French ‘Crédit Impôt Recherche’, or CIR) and other subsidies totaling €3.3 million in 2020 compared to €2.8 million in 2019. • General and Administrative Expenses. General and administrative expenses were €4 million for 2020 compared to €6.6 million for 2019, a decrease of €2.6 million, or 39%. This significant decrease was primarily linked to the fees and expenses incurred in 2019 in connection with our attempted listing on Nasdaq, and to cost reduction efforts related to personnel and structure expenses in 2020 compared to 2019. • Net Loss. Net loss was €17.1 million for 2020, as compared to €17.8 million for 2019. Net loss per share (based on weighted-average number of shares outstanding over the period except the treasury shares) was €0.28 in 2020 compared to €1.05 in 2019. The table below summarizes the non-audited operating results. (amounts in thousands euros, except for share data) 2019 2020Net Research and Development expenses (9,089) (9,921)General and administrative expenses (6,593) (4,021)Operating loss (15,682) (13,942)Net financial loss (2,134) (3,112)Loss before tax (17,816) (17,054)Income tax 28 - Net loss (17,788) (17,054)Non diluted weighted average number of shares outstanding, except treasury shares 16,882,661 59,974,486Loss per share (€/share) (1.05) (0.28) Summary of operational events (more details are provided in the corresponding press releases available on Biophytis's website: www.biophytis.com) Launch of the Phase 2-3 COVA study in patients with severe respiratory manifestation of COVID-19 In May 2020, Biophytis received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP), to proceed with its clinical development program COVA, a two-part study assessing Sarconeos (BIO101) in patients aged 45 and older, hospitalized with severe respiratory manifestations following COVID-19 infection;Biophytis received approvals for COVA from the UK Medicines Healthcare Products Regulatory Agency (MHRA) in June 2020, from the United States Food and Drug Administration (FDA) and the French Health Authority (ANSM) in July 2020 and the Brazilian Health Regulatory Agency (ANVISA) in August 2020;In August 2020, the first participant for Part 1 of the study was enrolled in Belgium;In October 2020, the first US and Brazilian patients were enrolled in COVA, with clinical centers opened and ready to recruit in Belgium, France, Brazil and the US. In December 2020, the first patient was enrolled in France;In February 2021, authorization for patient recruitment for Part 2 of COVA was obtained from regulatory authorities in Brazil, the United States, France and Belgium. Part 2 of COVA is a Phase 3 pivotal randomized study investigating the safety and efficacy of Sarconeos (BIO101) on the respiratory function from 310 COVID-19 patients (including the 50 patients from Part 1 of the study).The Company expects to report full results (For Part 1 and Part 2) in Q2 2021, subject to any delays in patient recruitment or retention, interruptions in sourcing or supply chain, regulatory authorizations and procedures, COVID-19-related delays, and the impact of the current pandemic. SARA clinical program in sarcopenia : In March 2020, due to COVID-19, Biophytis adapted the protocol of SARA-INT to allow patient follow up to take place at home, based on guidelines from regulators, including the U.S. FDA;In March 2020, Biophytis completed enrolment of the 233 patients into SARA-INT;In December 2020, the last patient in SARA-INT completed his final on-treatment visit;Biophytis expects to report top-line data from SARA-INT in Q2 2021, subject to any delays in patient recruitment or retention, interruptions in sourcing or supply chain, regulatory authorizations and procedures, COVID-19-related delays, and the impact of the current pandemic. MYODA clinical program in Duchenne Muscular Dystrophy (DMD): After an IND ‘‘may proceed’’ letter from the FDA (USA)in December 2019, in March 2020 Biophytis received approval from the Belgian FAMHP to proceed with its clinical investigation of Sarconeos (BIO101) in non-ambulatory patients with DMD.Depending on the evolution of the pandemic and its impact on our operational capabilities, the MYODA study is expected to start in H1 2021. Financing 1/ Debt financing: Replacement of the convertible ORNANEBSA from Negma by the convertible ORNANE from Atlas:In April 2020, the Company secured a new line of financing of €24 million from Atlas Special Opportunities LLC, a specialized investment fund based in New York (United States) providing for the issuance of 960 3-year note warrants. The 960 3-year note warrants require their holder to exercise them, at our request, in tranches of 120 warrants each. Each warrant grants its holder the right to one ORNANE. The ORNANE have a par value of €25,000. In April 2020, the Company formerly notified NEGMA Group LTD of its decision to terminate the contract signed in August 2019. The Negma agreement provided for up to €24 million in financing through the issuance of multiple tranches of convertible notes with attached warrants. This termination has led to litigation between Negma and Biophytis, and legal proceedings are ongoing. 2/ Equity raising: In 2020, the Company successfully raised capital through several transactions: Public offering of share subscription warrants: In April 2020, the Company closed a public offering of warrants to purchase ordinary shares, allowing shareholders registered as of April 8, 2020 to benefit from a non-negotiable and non-transferable subscription priority period and then new shareholders, to subscribe for warrants to purchase ordinary shares. Demands exceeded three times the number of available warrants. A total of 7,475,708 warrants were subscribed for total proceeds of €448 thousand. Private placement transactions : The Company successfully closed four private placement transactions which significantly strengthened its equity position. In February, June, July and October 2020, the Company issued shares to institutional investors totaling €3.3 million, €4 millions, €6.1 million and €10 million, respectively, and for a total of €23.4 million. Appointments:In January 2020, Biophytis appointed Evelyne Nguyen as Chief Financial Officer in replacement of Daniel Schneiderman. 2021 Outlook: Programs: The COVA study: The full results (Part 1 and Part 2) are expected in Q2 2021. Subject to any COVID-19 related delays, the Company anticipates applying for Emergency Use Authorization from FDA, and Conditional Market Approval from EMA in Q2 2021. The SARA -INT study: Following the last visit completion of the last patient in December 2020, the Company is preparing to release top-line results of this Phase 2 trial during Q2 2021. The MYODA study: Depending on the evolution of the COVID-19 pandemic, the Company is intending to start in H1 2021 the Phase 1-3 MYODA trial. These plans remain subject to any delays in patient recruitment or retention, interruptions in sourcing or supply chain, regulatory authorizations and procedures, COVID-19-related delays, and the impact of the current pandemic. Nasdaq IPO: On February 12, 2021, the Company closed its previously announced initial public offering on the Nasdaq Capital Market by way of a capital increase of 12,000,000 ordinary shares represented by 1,200,000 American Depositary Shares (“ADSs”), with each ADS representing 10 ordinary shares, at a price of $16.75 per ADS. Total gross proceeds were approximately $20.1 million. The Company received net proceeds of approximately $16.35 million or €13.5 million, after deducting underwriting discounts and commissions, management fee and estimated offering expenses payable by the Company. Since February 10, 2021, Biophytis ADSs are listed on Nasdaq Capital Market (US trading ticker: BPTS) Coronavirus StatementWe are closely monitoring how the spread of COVID-19 is affecting our employees, business, preclinical and clinical studies. As part of our COVID-19 pandemic response, most of our employees have transitioned to working remotely and travel has been restricted. During the pandemic, we instructed our employees to work remotely as much as possible except for essential and required activities that needed to be performed in laboratories. Such access and work must comply with social distancing and other local government and facility requirements and policies were implemented during initial and subsequent waives of COVID-19. While we have substantially completed enrollment dosing of Sarconeos (BIO101) in our SARA-INT study, limitations on in-office visits due to study site closures during the initial COVID-19 wave required adaptation of the study protocol including closing on-site activities, organizing patient follow-ups to take place at home, and expanding treatment from six to nine months for some patients. All such changes to the protocol were submitted to, reviewed and approved by reviewing IRBs. Despite these impediments, the last patient completed his final on treatment visit in December 2020.However, the impact of continued and prolonged disruptions caused by the COVID-19 pandemic may result in further difficulties or delays in initiating, enrolling, conducting or completing our ongoing and planned clinical trials, which could result in additional unforeseen costs. The impact of COVID-19 on our future clinical research and development progress will largely depend on future developments of the pandemic. These future COVID-19 developments are highly uncertain and cannot be predicted with confidence, and include issues such as: the rate and ultimate geographic spread of the disease; the duration of the pandemic; travel restrictions and social distancing requirements in the U.S., Brazil, the UK, France and other countries; business disruptions and closures; impact on financial markets and the global economy; and the effectiveness of actions taken to contain, treat and prevent the disease. About BIOPHYTISBiophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS - ISIN: FR0012816825), and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com DisclaimerThis press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding Biophytis’ anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, the impact of the current pandemic on the Company’s clinical trials and other risks described in our filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company’s Half Year 2020 Report available on BIOPHYTIS website (www.biophytis.com). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Biophytis Contact for Investor RelationsEvelyne Nguyen, CFO email@example.com Media contactLife Sci Advisor Sophie Baumont/Chris Maggos/John HodgsonE: firstname.lastname@example.orgT: +33 6 27 74 74 49 Investor RelationsLifeSci Advisors, LLC Sandya von der Weid E: email@example.comT: +41 78 680 05 38